These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 34503964)

  • 21.
    Cytryn SL; Pandit-Taskar N; Lumish MA; Maron SB; Gu P; Ku GY; Chou JF; Capanu M; Antoine A; Loegel D; Feder L; Philemond S; Lyashchenko SK; Lewis JS; Paroder V; Srivastava A; Tang LH; Schoder H; Janjigian YY
    J Nucl Med; 2024 May; 65(5):722-727. PubMed ID: 38514081
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Zhao Y; Ren J
    Front Immunol; 2023; 14():1266843. PubMed ID: 38035081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Negative Correlation Between
    Wu L; Liu J; Wang S; Bai M; Wu M; Gao Z; Li J; Yu J; Liu J; Meng X
    Front Endocrinol (Lausanne); 2022; 13():913631. PubMed ID: 35846323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Organ-specific accuracy of [
    Gideonse BM; Birkeland M; Vilstrup MH; Grupe P; Naghavi-Behzad M; Ruhlmann CH; Gerke O; Hildebrandt MG
    Jpn J Radiol; 2024 Jul; 42(7):753-764. PubMed ID: 38504000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Positron Emission Tomography Imaging of Programmed Death 1 Expression in Cancer Patients Using 124I-Labeled Toripalimab: A Pilot Clinical Translation Study.
    Wang S; Zhu H; Ding J; Wang F; Meng X; Ding L; Zhang Y; Li N; Yao S; Sheng X; Yang Z
    Clin Nucl Med; 2021 May; 46(5):382-388. PubMed ID: 33512952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can Baseline [
    Bianchi A; De Rimini ML; Sciuto R; Annovazzi A; Di Traglia S; Bauckneht M; Lanfranchi F; Morbelli S; Nappi AG; Ferrari C; Rubini G; Panareo S; Urso L; Bartolomei M; D'Arienzo D; Valente T; Rossetti V; Caroli P; Matteucci F; Aricò D; Bombaci M; Caponnetto D; Bertagna F; Albano D; Dondi F; Gusella S; Spimpolo A; Carriere C; Balma M; Buschiazzo A; Gallicchio R; Storto G; Ruffini L; Scarlattei M; Baldari G; Cervino AR; Cuppari L; Burei M; Trifirò G; Brugola E; Zanini CA; Alessi A; Fuoco V; Seregni E; Deandreis D; Liberini V; Moreci AM; Ialuna S; Pulizzi S; Evangelista L
    Cancer Biother Radiopharm; 2023 May; 38(4):256-267. PubMed ID: 37098169
    [No Abstract]   [Full Text] [Related]  

  • 27. Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point
    Cho SY; Lipson EJ; Im HJ; Rowe SP; Gonzalez EM; Blackford A; Chirindel A; Pardoll DM; Topalian SL; Wahl RL
    J Nucl Med; 2017 Sep; 58(9):1421-1428. PubMed ID: 28360208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The prognostic value of [
    Sachpekidis C; Weru V; Kopp-Schneider A; Hassel JC; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2699-2714. PubMed ID: 37099131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer
    Stutvoet TS; van der Veen EL; Kol A; Antunes IF; de Vries EFJ; Hospers GAP; de Vries EGE; de Jong S; Lub-de Hooge MN
    J Nucl Med; 2020 Dec; 61(12):1839-1844. PubMed ID: 32358092
    [No Abstract]   [Full Text] [Related]  

  • 30. Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy.
    Marandino L; Capozza A; Bandini M; Raggi D; Farè E; Pederzoli F; Gallina A; Capitanio U; Bianchi M; Gandaglia G; Fossati N; Colecchia M; Giannatempo P; Serafini G; Padovano B; Salonia A; Briganti A; Montorsi F; Alessi A; Necchi A
    Eur Urol Focus; 2021 Sep; 7(5):1092-1099. PubMed ID: 33172772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive value and accuracy of [
    Ayati N; Jamshidi-Araghi Z; Hoellwerth M; Schweighofer-Zwink G; Hitzl W; Koelblinger P; Pirich C; Beheshti M
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2715-2726. PubMed ID: 37140669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients.
    Zhou X; Jiang J; Yang X; Liu T; Ding J; Nimmagadda S; Pomper MG; Zhu H; Zhao J; Yang Z; Li N
    J Nucl Med; 2022 Apr; 63(4):536-542. PubMed ID: 34326125
    [No Abstract]   [Full Text] [Related]  

  • 33. Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients.
    Kudura K; Dimitriou F; Basler L; Förster R; Mihic-Probst D; Kutzker T; Dummer R; Mangana J; Burger IA; Kreissl MC
    Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma.
    Ferdinandus J; Zaremba A; Zimmer L; Umutlu L; Seifert R; Barbato F; Ugurel S; Chorti E; Grünwald V; Herrmann K; Schadendorf D; Fendler WP; Livingstone E
    Cancer Imaging; 2022 Feb; 22(1):11. PubMed ID: 35123578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Whole-body F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography imaging in the follow-up of metastatic uveal melanoma.
    Klingenstein A; Haug AR; Nentwich MM; Tiling R; Schaller UC
    Melanoma Res; 2010 Dec; 20(6):511-6. PubMed ID: 20890225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The utility of
    Kitajima K; Kawanaka Y; Komoto H; Minami T; Yokoi T; Kuribayashi K; Kijima T; Nakamura A; Hashimoto M; Kondo N; Hasegawa S; Yamakado K
    Hell J Nucl Med; 2021; 24(3):186-198. PubMed ID: 34901959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The influence of metastatic patterns and tumor load on therapeutic efficacy of immunotherapy in patients with metastatic melanoma as determined by quantitative PET-parameters using [ 18 F]-fluorodeoxyglucose PET/computed tomography.
    Berberich C; Mustafa M; Zhuwu Y; Gaa J; Krackhardt A; Nekolla SG
    Melanoma Res; 2023 Jun; 33(3):199-207. PubMed ID: 36866631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma.
    Amrane K; Le Goupil D; Quere G; Delcroix O; Gouva S; Schick U; Salaun PY; Abgral R; Alavi Z; Keromnes N; Querellou S
    Medicine (Baltimore); 2019 Jul; 98(29):e16417. PubMed ID: 31335691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanobody-mediated SPECT/CT imaging reveals the spatiotemporal expression of programmed death-ligand 1 in response to a CD8
    Ertveldt T; Meulewaeter S; De Vlaeminck Y; Olarte O; Broos K; Van Calenbergh S; Bourgeois S; Deprez J; Heremans Y; Goyvaerts C; Staels W; De Smedt S; Dewitte H; Devoogdt N; Keyaerts M; Verbeke R; Barbé K; Lentacker I; Breckpot K
    Theranostics; 2023; 13(15):5483-5500. PubMed ID: 37908728
    [No Abstract]   [Full Text] [Related]  

  • 40. Correlation of PD-L1 expression on tumor cell and tumor infiltrating immune cell with 18F-fluorodeoxyglucose uptake on PET/computed tomography in surgically resected pulmonary adenocarcinoma.
    Hu B; Xiao J; Xiu Y; Fu Z; Shi H; Cheng D
    Nucl Med Commun; 2020 Mar; 41(3):252-259. PubMed ID: 32068670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.